Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Uplekh Purewal

Pain Medicine Philadelphia, PA Medical Doctor

NPI 1548203839 CMS profile 296341

9815 Roosevelt Blvd, Philadelphia, PA 19114

Open in the dashboard

General payments

$20,933

541 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Uplekh Purewal of Philadelphia, PA is reported in the CMS Open Payments database as having received $20,933 across 541 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,812 100
2024 General $2,798 84
2023 General $1,803 55
2022 General $1,761 54
2021 General $1,689 71
2020 General $1,029 42
2019 General $9,041 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Uplekh Purewal
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Uplekh Purewal were reported at $2,812. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Uplekh Purewal Pain Medicine median Middle half National median
2019 $9,041 $506 $144–$1,566 $163
2020 $1,029 $315 $96–$934 $114
2021 $1,689 $452 $134–$1,237 $132
2022 $1,761 $475 $124–$1,407 $149
2023 $1,803 $480 $136–$1,384 $160
2024 $2,798 $521 $164–$1,511 $164
2025 $2,812 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $7,450 285 payments
  2. Horizon Therapeutics plc $2,968 5 payments
  3. Vertiflex, Inc. $2,644 9 payments
  4. Nevro Corp. $2,600 55 payments
  5. Boston Scientific Corporation $921 56 payments
  6. Flexion Therapeutics, Inc. $603 14 payments
  7. Globus Medical, Inc. $594 21 payments
  8. Vertos Medical, Inc. $551 13 payments
  9. Curonix LLC $418 7 payments
  10. Medtronic, Inc. $368 17 payments
  11. Other $1,815 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,595 527 payments
  2. Honoraria $2,840 3 payments
  3. Travel and Lodging $2,322 6 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $103 2 payments
  5. Education $74 3 payments
Products named General payments · program years 2019–2025
  1. RAYOS Rayos $2,968 5 payments
  2. RAYOS Rayos $2,968 5 payments
  3. RAYOS Rayos $2,968 5 payments
  4. Superion ISS $2,644 9 payments
  5. PROCLAIM $1,742 51 payments
  6. Senza $1,163 26 payments
  7. Proclaim Family of SCS IPGs $1,146 45 payments
  8. OCTRODE $887 34 payments
  9. Proclaim IPG $860 41 payments
  10. Senza Spinal Cord Stimulation System $827 20 payments
  11. Other $8,853 326 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,301

Median for Pain Management: 951

Drug cost

$22,806

Median for Pain Management: $26,034

Branded share of claims

18.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 16 $6,145
Pregabalin Generic 152 $2,465
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 146 $2,166
Lidocaine Generic 25 $2,019
Oxycodone Hcl Generic 145 $1,759
Gabapentin Generic 154 $1,563
Cephalexin Generic 119 $1,475
Cyclobenzaprine Hcl Generic 78 $811
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 42 $787
Endocet Oxycodone Hcl/Acetaminophen Brand 25 $523

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$203,567

Of which drugs: $961

Medicare patients

479

Average age 68

Services billed

2,917

286 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 35%
Ischemic heart disease 29%
COPD 23%
Chronic kidney disease 21%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 47 631 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

541 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record